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Stroke etiologies in patients with COVID-19:
the SVIN COVID-19 multinational registry
María E. Ramos-Araque1,2, James E. Siegler3*, Marc Ribo4,5, Manuel Requena4,5, Cristina López2, Mercedes de Lera2,
Juan F. Arenillas2, Isabel Hernández Pérez2, Beatriz Gómez-Vicente2, Blanca Talavera2, Pere Cardona Portela6,
Ana Nuñez Guillen6, Xabier Urra7, Laura Llull7, Arturo Renú7, Thanh N. Nguyen8, Dinesh Jillella9, Fadi Nahab9,
Raul Nogueira10, Diogo Haussen10, Ryna Then3, Jesse M. Thon3, Luis Rodríguez Esparragoza11,
Maria Hernández-Pérez11, Alejandro Bustamante11, Ossama Yassin Mansour12, Mohammed Megahed13,
Tamer Hassan14, David S. Liebeskind15, Ameer Hassan16,17, Saif Bushnaq18, Mohamed Osman18,
Alejandro Rodriguez Vazquez7 and SVIN Multinational Registry and Task Force

Abstract
Background and purpose: Coronavirus disease 2019 (COVID-19) is associated with a small but clinically significant
risk of stroke, the cause of which is frequently cryptogenic. In a large multinational cohort of consecutive COVID-19
patients with stroke, we evaluated clinical predictors of cryptogenic stroke, short-term functional outcomes and inhospital mortality among patients according to stroke etiology.
Methods: We explored clinical characteristics and short-term outcomes of consecutively evaluated patients 18 years
of age or older with acute ischemic stroke (AIS) and laboratory-confirmed COVID-19 from 31 hospitals in 4 countries
(3/1/20–6/16/20).
Results: Of the 14.483 laboratory-confirmed patients with COVID-19, 156 (1.1%) were diagnosed with AIS. Sixty-one
(39.4%) were female, 84 (67.2%) white, and 88 (61.5%) were between 60 and 79 years of age. The most frequently
reported etiology of AIS was cryptogenic (55/129, 42.6%), which was associated with significantly higher white
blood cell count, c-reactive protein, and D-dimer levels than non-cryptogenic AIS patients (p</=0.05 for all
comparisons). In a multivariable backward stepwise regression model estimating the odds of in-hospital mortality,
cryptogenic stroke mechanism was associated with a fivefold greater odds in-hospital mortality than strokes due to
any other mechanism (adjusted OR 5.16, 95%CI 1.41–18.87, p = 0.01). In that model, older age (aOR 2.05 per decade,
95%CI 1.35–3.11, p < 0.01) and higher baseline NIHSS (aOR 1.12, 95%CI 1.02–1.21, p = 0.01) were also independently
predictive of mortality.
Conclusions: Our findings suggest that cryptogenic stroke among COVID-19 patients carries a significant risk of
early mortality.
Keywords: Stroke, COVID-19, Coronavirus, Cryptogenic, Mortality
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Introduction
Since December 2019, coronavirus disease 2019
(COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a pandemic infecting more than 81 million people worldwide
and causing more than 1.700.000 deaths [1]. Although
respiratory symptoms are most commonly reported,
neurological symptoms are increasingly recognized, and
range from 36 to 56% according to large series of hospitalized patients [2–4], with a small but clinically significant risk of acute ischemic stroke (AIS) [5–7].
Potential mechanisms of SARS-CoV-2-associated
stroke have been described and include a prothrombotic
state [3, 8, 9], hyperinflammatory response, cardiomyopathy and endothelial injury from direct viral invasion
[10–12]. Among hospitalized patients, COVID-19 has
been recognized as an independent predictor of AIS and
is associated with poor outcomes with considerable early
mortality in small observational cohorts [13, 14]. The
aim of this study was to characterize clinical, radiographic, and laboratory predictors of cryptogenic stroke
using a multinational registry, and to evaluate shortterm outcomes of patients with SARS-CoV-2 associated
stroke according to traditional stroke mechanisms.
Methods
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cardiac sources of embolism, large artery atherosclerotic
stenosis, and small vessel disease. Patients with incomplete workup were also considered to have cryptogenic
infarcts. Pre-morbid and discharge functional status
were determined using the modified Rankin Scale [16,
17]. Neuroimaging was performed at the discretion of
the treating physician and radiographic findings (e.g., location of infarction, presence of an intracranial occlusion) were reported by local site investigators. Each
center reported their in-hospital mortality rate among
all COVID-19 patients throughout the study period.
Data were recorded on a HIPAA-compliant, online
registry, as previously described [18]. Data elements with
< 50% completion rate (e.g., erythrocyte sedimentation
rate) were not reported in order to limit selection bias.
Outcome measures

The primary study outcome was the diagnosis of a
cryptogenic (undetermined) mechanism of stroke. Secondary outcomes included discharge disability (according to mRS), discharge disposition, and in-hospital
mortality among patients with COVID-19 when stratified by cause of acute ischemic stroke. To maximize specificity of findings, patients with more than one possible
stroke mechanism (n = 9) were excluded from comparative analyses involving stroke mechanisms.

Study design and participants

Between 3/1/2020 and 6/16/2020, we pooled consecutive
patients >/= 18 years of age hospitalized or evaluated in
the emergency department (ED) with AIS and confirmed
diagnosis of COVID-19 by oropharyngeal polymerase
chain reaction (PCR) or IgG and/or IgM antibody in
sera, using local commercial assays, in 31 hospitals
across 4 countries. A more detailed summary of the
Methods has been previously described [7]. Informed
consent was waived by the local institutional review
board at each participating center. No sample size calculations were made for this study as analyses were exploratory and hypothesis-generating. The results of this
investigation are reported in accordance with the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) statement.
Data collection

Demographic, clinical, and laboratory findings (including
method of COVID-19 diagnosis), as well as stroke treatment (including intravenous thrombolysis, endovascular
thrombectomy, and antithrombotic therapy), and shortterm functional outcomes at time of discharge were collected. Stroke etiology was determined by local site investigators (vascular neurologists) using a modified Trial
of ORG 10172 in Acute Stroke Treatment (TOAST)
classification [15]. Cryptogenic stroke was defined as
stroke of undetermined etiology after exclusion of

Statistical analysis

Normality of continuous data was assessed histographically and confirmed using the Shapiro-Wilk test. Nonnormally distributed continuous variables are summarized as medians with interquartile range. Categorical
variables are presented as frequencies (%). Descriptive
statistics were used to compare groups, with the χ2 test
for discrete variables (or Fisher’s exact test when cell
counts were 5 or less), and the Wilcoxon Rank-sum test
or Kruskal-Wallis equality of populations rank test for
non-normally distributed continuous variables, as appropriate. Bivariate analyses were performed to associate
baseline variables with the occurrence of endpoints.
Backward stepwise logistic regression was performed to
estimate the association between clinical, laboratory, and
radiographic findings with the primary and secondary
outcomes. Estimates of association are presented as odds
ratios (OR) and respective 95% confidence intervals (CI),
with adjustment for all variables significant to p < 0.2 on
the respective bivariate analysis. Variables were eliminated from each adjusted model if they were no longer
significant to p < 0.2. All adjusted regression models
were clustered by site. Using the remaining variables
from the final backward stepwise regression model for
mortality, we created a simple index assigning 1-point to
each variable (age, male sex, history of diabetes, NIHSS,
and cryptogenic stroke; Supplementary Table 1). In
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order to reduce overfitting, NIHSS was stratified such
that one point was assigned for values ≥10 and age
stratified such that one point was assigned if the patient
were ≥ 60 years old based on visual association of these
thresholds with respect to associated risk of mortality
(Supplementary Figs. 1 and 2). The mortality rate of the
cohort was assessed for each point value. A receiver operating characteristic curve was generated to test the association between the mortality score and in-hospital
mortality. Model performance was assessed using the cstatistic with 95% CI. The statistical significance level of
all tests was defined as a p-value ≤0.05. As this was an
exploratory study, no adjustments were made for multiple comparisons. P-values are provided for conventional purposes only and should be interpreted with
caution. All tests were performed at the two-sided level
using STATA (College Station, TX) version 15.0. Missing data were not imputed. Fully de-identified data can
be made available upon reasonable request of the corresponding author.

Results
Clinical features

Of the 14,483 laboratory-confirmed SARS-CoV-2 patients, 156 (1.1%) were diagnosed with a clinical and/or
radiographic acute ischemic stroke. Antecedent systemic
symptoms were reported with variable frequency but included fever in 69/134 patients (51%), 77/133 (58%) with
cough, 60/128 (47%) dyspnea, 21/112 (19%) chest pain,
18/107 (17%) myalgias, 12/110 (11%) headache, and <
10% with symptoms of congestion, dizziness, odynophagia, hyposmia, or hypogeusia. Among stroke patients,
61/155 (39.4%) were female, 84/125 (67.2%) White, and
more than half of patients (n = 88/143, 61.5%) were between 60 and 79 years of age. Seventeen of 145 patients
(11.7%) received intravenous thrombolysis, and 14/156
(9.0%) were reported to experience any intracerebral
hemorrhage—1 patient experienced a NIHSS worsening
of 4 points attributed to a parenchymal hematoma, however this patient did not receive intravenous thrombolysis or thrombectomy.
The etiology of stroke was reported in 129 of 156
stroke patients (82.7%), with cryptogenic being commonly reported (n = 55, 42.6%). Compared to patients
with any other defined stroke mechanism (or multiple
possible mechanisms), patients with cryptogenic stroke
were more frequently Hispanic (51.0% vs. 33.3%, p =
0.05), had less atrial fibrillation (p < 0.01) and congestive
heart failure (p = 0.05; Table 1).
There was no difference with respect to age, sex, race,
or history of pre-morbid disability among patients with
cryptogenic versus known stroke mechanisms.
In a separate analysis of 11 sites included in this study
which submitted data of ischemic stroke patients
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irrespective of SARS- CoV-2 infection during a similar
period the year prior (3/1/19–05/31/19), the prevalence
of cryptogenic (unspecified or undetermined) stroke was
19.7% (260/1319 patients) [19]. Using a two-sample test
of proportions, the rate of cryptogenic stroke was significantly higher in this population of COVID-19-associated
stroke (42.6% vs. 19.6%, p < 0.001). Furthermore, the reported in-hospital mortality rate among these patients
was also significantly greater than in this historic control
group (38.1% vs. 7.8%, p < 0.001).
On admission, neurological deficits according to baseline NIHSS were generally moderate-to-severe among all
patients, with more severe deficits noted in patients with
strokes due to a cryptogenic mechanism, cardioembolism, or other identifiable mechanism, compared to patients with large or small vessel disease (p = 0.02;
Table 2).
Compared to non-cryptogenic stroke patients, those
with cryptogenic strokes had no difference in baseline
NIHSS (p = 0.53). Patients with cardioembolic stroke
had more frequently identified intracranial arterial occlusions and cortical involvement compared to other
stroke mechanisms (p < 0.05 for both findings), followed
by cryptogenic stroke. Admission white blood cell count,
C-reactive protein and D-dimer levels were significantly
greater for patients with cryptogenic stroke when compared to all other stroke groups, and after multivariable
regression with adjustment for all candidate variables
significant to p < 0.2 (Hispanic ethnicity, congestive heart
failure, cortical infarction, white blood cell count and Ddimer), only congestive heart failure was statistically significantly and inversely associated with cryptogenic
stroke mechanism (p < 0.01; Table 3).
Patients with strokes due to cardioembolism and a
cryptogenic mechanism had a significantly higher risk of
any hemorrhagic transformation when compared to
strokes of all other classifications, although event rates
for strokes due to ‘other’ causes and small vessel disease
were low (p = 0.05; Table 4). Patients with cryptogenic
stroke were non-significantly more likely to be discharged with greater disability than strokes of other
mechanisms (p = 0.07), despite having a similar premorbid functional status. Furthermore, cryptogenic
stroke patients had a significantly higher risk of inhospital mortality when compared to strokes of all other
mechanisms (OR 2.27, 95%CI 1.01–5.08, p = 0.05). In the
backward stepwise regression model for in-hospital mortality, cryptogenic stroke remained independently associated with in-hospital mortality (aOR 5.16, 95%CI 1.41–
18.87, p = 0.01). In that model, older age (aOR 2.05 per
decade, 95%CI 1.35–3.11, p < 0.01), higher baseline
NIHSS (aOR 1.12, 95%CI 1.02–1.21, p = 0.01), and history of diabetes (aOR 6.89, 95%CI 1.02–46.76, p = 0.05)
remained independently associated with mortality,

Ramos-Araque et al. BMC Neurology

(2021) 21:43

Page 4 of 11

Table 1 Demographic data
p-valueb

p-valuec

0.10

0.97

0.08

0.45

0.52

> 0.9

0.02

0.05

0.11

0.83

2/11 (18.2)

0.82

0.69

4/4 (100)

4/11 (36.4)

0.10

0.87

2/4 (50.0)

7/11 (63.6)

0.56

0.87

All patients acute
ischemic strokea
(n = 156)

Cryptogenic
stroke
(n = 55)

Cardioembolic
stroke
(n = 35)

Large vessel
stroke
(n = 15)

Small vessel
stroke
(n = 4)

Other
(n = 11)

< 30

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

30–39

3 (2.5)

1 (1.8)

2 (5.7)

0 (0)

0 (0)

2 (18.2

40–49

12 (10.0)

6 (10.9)

2 (5.7)

0 (0)

0 (0)

4 (36.4)

50–59

15 (12.5)

6 (10.9)

5 (14.3)

2 (13.3)

0 (0)

2 (18.2)

60–69

36 (30.0)

19 (34.6)

8 (22.9)

6 (40.0)

1 (25.0)

2 (18.2)

70–79

37 (30.8)

16 (29.1)

13 (37.1)

5 (33.3)

2 (50.0)

1 (9.1)

80–89

12 (10.0)

5 (9.1)

4 (11.4)

2 (13.3)

1 (25.0)

0 (0)

> 89

5 (4.2)

2 (3.6)

3 (8.6)

0 (0)

0 (0)

0 (0)

Sex, no. female (%)

61/155 (39.4)

19/55 (34.6)

15/35 (42.9)

5/14 (35.7)

0/4 (0)

8/11 (72.7)

White

84/125 (67.2)

31/45 (68.9)

21/28 (75.0)

9/12 (75.0)

2/3 (66.7)

5/10 (50.0)

Black

35/125 (28.0)

12/45 (26.7)

7/28 (25.0)

2/12 (16.7)

1/3 (33.3)

4/10 (40.0)

Asian

2/125 (1.6)

1/45 (2.2)

0/28 (0)

0/12 (0)

0/3 (0)

0/10 (0)

More than one race

2/125 (1.6)

1/45 (2.2)

0/28 (0)

1/12 (8.3)

0/3 (0)

0/10 (0)

Other

2/125 (1.6)

0/45 (0)

0/28 (0)

0/12 (0)

0/3 (0)

1/10 (0)

Hispanic ethnicity, no. (%)

58/140 (41.4)

25/49 (51.0)

10/33 (30.3)

4/12 (33.3)

4/4 (100)

10/11 (90.9)

Nasopharyngeal PCR

153 (98.1)

55/55 (100)

35/35 (100)

15/15 (100)

4/4 (100)

10/11 (90.9)

Serum IgM and/or IgG

6 (3.8)

2/55 (3.6)

3/35 (8.6)

0/15 (0)

1/4 (25.0)

1/11 (9.1)

Known COVID-19 exposure, no. (%)

19 (12.2)

8/55 (14.6)

5/35 (14.3)

1/15 (6.7)

0/4 (0)

Hypertension

111/154 (72.1)

38/53 (71.7)

26/35 (74.3)

12/15 (80.0)

Diabetes mellitus

65/152 (42.8)

22/51 (43.1)

13/35 (37.1)

5/15 (33.3)

Age, no. (%)

Race, no. (%)

d

Diagnosis of COVID-19 , no. (%)

Medical history, no. (%)

Dyslipidemia

58/142 (40.9)

18/53 (34.0)

17/35 (48.9)

7/15 (46.7)

3/4 (75.0)

0/11 (0)

0.01

0.33

Atrial fibrillation

22/148 (14.9)

0/52 (0)

16/35 (45.7)

0/15 (0)

0/4 (0)

0/11 (0)

< 0.01

< 0.01

Congestive heart failure

27/154 (17.5)

5/53 (9.4)

9/35 (25.7)

4/15 (26.7)

0/4 (0)

1/11 (9.1)

0.17

0.05

Active tobacco use

15/145 (10.3)

4/52 (7.7)

5/33 (15.2)

0/15 (0)

1/4 (25.0)

0/11 (0)

0.21

0.68

Prior stroke

15/140 (10.7)

6/42 (12.5)

2/33 (6.1)

0/13 (0)

0/4 (0)

0/11 (0)

0.59

0.33

Chronic renal insufficiency
(stage III/IV or dialysis-dependent)

16/144 (11.1)

3/47 (6.4)

1/33 (3.0)

2/13 (15.4)

0/4 (0)

3/11 (27.3)

0.11

0.49

Chronic obstructive pulmonary
disease and/or asthma

11/135 (8.2)

2/48 (4.2)

3/33 (9.1)

0/13 (0)

1/4 (25.0)

0/11 (0)

0.28

0.24

Cancer

8/134 (6.0)

4/47 (8.5)

1/33 (2.9)

0/13 (0)

1/4 (25.0)

0/11 (0)

0.29

0.35

Premorbid mRS, median (IQR)

0 (0–1)
(n = 124)

0 (0–0)
(n = 49)

0 (0–1)
(n = 33)

0 (0–0)
(n = 13)

0 (0–1)
(n = 4)

0 (0–0)
(n = 10)

0.54

> 0.9

Of the 11 patients with ‘Other’ etiologies, 2 had hypercoagulable states due to malignancy, 1 with hypercoagulability on laboratory testing unrelated to
malignancy, 2 with arterial dissection, 1 with vasculitis due to mucormycosis, 3 with radiographic findings of posterior reversible encephalopathy with infarction,
and 2 with etiologies not otherwise specified
a
Acute ischemic stroke includes suspected or radiographically-confirmed cases, and in patients with multiple possible stroke mechanisms (n = 9). Patients
with multiple stroke mechanisms were not included in the subsequent columns in order to minimize heterogeneity
b
P-values indicate categorical comparisons between all stroke subtypes
c
P-values indicate comparisons between cryptogenic and non-cryptogenic stroke subtypes (including strokes due to multiple possible etiologies)
d
3 patients with an acute ischemic stroke were diagnosed with COVID-19 using both serum antibodies and nasopharyngeal PCR. COVID-19 denotes
coronavirus disease 2019, PCR polymerase chain reaction

whereas male sex was slightly but non-significantly associated with mortality (aOR 2.39, 95%CI 0.69–8.28, p =
0.17; supplementary Table 1). Neither intravenous
thrombolysis (OR 0.82, 95%CI 0.27–2.52, p = 0.73) nor
thrombectomy (OR 0.97, 95%CI 0.40–2.34, p = 0.95)

were associated with mortality in univariate modeling. A
simple risk score was derived from the five variables
from the backward stepwise regression model by assigning 1-point each in order to estimate the risk of inhospital mortality. Additional points showed an
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Table 2 Clinical, laboratory, and radiographic measures and management
All patients acute Cryptogenic Cardioembolic Large vessel Small vessel Other
stroke
stroke
stroke
(n = 11)
ischemic strokea stroke
(n = 156)
(n = 55)
(n = 35)
(n = 15)
(n = 4)

p-valueb p-valuec

Baseline NIHSS median, (IQR)

13 (5–21)
(n = 130)

12 (6–23)
(n = 48)

14 (6–21)
(n = 32)

8 (4–11)
(n = 14)

2 (1–2)
(n = 4)

21 (9–22)
(n = 10)

0.02

0.53

Head CT performed, no. (%)

135/151 (89.4)

48/55 (87.3)

34/35 (97.1)

14/15 (93.3)

4/4 (100)

10/11
(90.9)

0.56

0.25

Clinical and radiographic findings

First CT indicating acute stroke, no. (%)

76/132 (57.6)

33/48 (68.8)

21/34 (61.8)

10/14 (71.4)

0/4 (0)

4/10 (40.0) 0.04

0.10

CT angiogram performed, no. (%)

99/151 (65.6)

36/55 (65.5)

23/35 (65.7)

14/15 (93.3)

4/4 (100)

10/11
(90.9)

0.07

0.36

Intracranial occlusion, no. (%)

53/107 (49.5)

17/37 (46.0)

17/24 (70.8)

6/14 (42.9)

0/4 (0)

3/10 (30.0) 0.04

0.70

MRI brain performed, no. (%)

55/151 (36.4)

21/55 (38.2)

11/35 (31.4)

5/15 (33.3)

1/4 (25.0)

8/11 (72.7) 0.17

> 0.9

MRI evidence of acute stroke, no. (%)

45/55 (81.8)

15/21 (71.4)

9/11 (81.8)

5/5 (100)

1/1 (100)

8/8 (100)

0.42

0.05

Cortical

81/101 (80.2)

29/39 (74.4)

26/28 (92.9)

11/12 (91.7)

0/2 (0)

10/10
(100)

< 0.01

0.09

Subcortical supratentorial

54/101 (53.5)

18/39 (46.2)

15/28 (53.6)

5/12 (41.7)

2/2 (0)

7/10 (70.0) 0.43

0.38

Infratentorial

12/101 (11.9)

7/39 (18.0)

0/28 (0)

1/12 (8.3)

0/2 (0)

1/10 (10.0) 0.12

0.11

D-dimer (mcg/mL), median (IQR)

0.78 (0.13–4.9)
(n = 87)

1.05
(0.21–9.15)
(n = 36)

0.14 (0.05–0.21) 0.61
(n = 18)
(0.14–10.08)
(n = 8)

0.07, 0.49
(n = 2)

0.26
(0.13–1.3)
(n = 6)

0.04

0.02

Admission platelet count (cells/μL), median
(IQR)

223 (183–313)
(n = 143)

242
(201–321)
(n = 53)

221 (183–289)
(n = 34)

259
(188–353)
(n = 15)

198
(106–326)
(n = 4)

212
(150–281)
(n = 9)

0.34

0.25

C-reactive protein peak (mg/dL), median
(IQR)

11 (3–25)
(n = 96)

15.8
(6.2–52.7)
(n = 38)

4.2 (2.4–12.7)
(n = 23)

12.9
(0.8–74.9)
(n = 11)

6.2 (0.7–49.9) 11.6
(n = 3)
(9.5–58.9)
(n = 4)

0.14

0.05

Admission WBC (cells/μL), median (IQR)

8.4 (6.5–11.9)
(n = 139)

10.7
(6.8–14.4)
(n = 53)

8.0 (6.5–10.8)
(n = 35)

6.8 (5.8–9.5)
(n = 15)

7.7 (5.7–9.3)
(n = 4)

6.4
(5.5–6.7)
(n = 9)

0.05

0.01

Lymphocyte count (cells/μL), median (IQR)

1.2 (0.7–1.7)
(n = 132)

1.3 (0.7–1.8)
(n = 47)

1.4 (1.0–1.9)
(n = 32)

0.7 (0.7–1.1)
(n = 15)

1.7 (1.2–1.8)
(n = 4)

1.4
(0.7–1.5)
(n = 9)

0.05

0.60

CT or MRI location of infarction, no. (%)

Laboratory testing

Treatment
Intravenous thrombolysis, no. (%)

17/145 (11.7)

4/54 (7.4)

7/35 (20.0)

3/15 (20.0)

0/4 (0)

2/11 (18.2) 0.31

0.12

Endovascular treatment, no. (%)

33/114 (29.0)

8/42 (19.1)

14/26 (53.9)

4/10 (40.0)

0/3 (0)

2/7 (28.9)

0.03

0.03

Endovascular treatment d, no. (%)

33/53 (62.3)

8/17 (47.1)

14/17 (82.4)

4/6 (66.7)

n/a

2/3 (66.7)

0.18

0.11

0.01

0.17

Acute antithrombotic treatment e, no. (%)
Single or dual antiplatelet therapy
Therapeutic anticoagulation
None

f

66/108 (61.1)

31/43 (72.1)

13/30 (43.3)

12/12 (100)

2/3 (66.7)

6/10 (60.0)

22/108 (20.4)

5/43 (11.6)

11/30 (36.7)

0/12 (0)

1/3 (33.3)

1/10 (10.0)

20/108 (18.5)

7/43 (16.3)

6/30 (20.0)

0/12 (0)

0/3 (0)

3/10 (30.0)

a

Acute ischemic stroke includes suspected or radiographically-confirmed cases, and in patients with multiple possible stroke mechanisms (n = 9). Patients
with multiple stroke mechanisms were not included in the subsequent columns in order to minimize heterogeneity
b
P-values indicate categorical comparisons between all stroke subtypes
c
P-values indicate comparisons between cryptogenic and non-cryptogenic stroke subtypes (including strokes due to multiple possible etiologies)
d
Analysis limited to patients with any intracranial occlusion on vascular imaging
e
Acute antithrombotic treatment was defined as use of an antithrombotic within 24 h of ischemic stroke diagnosis, or between 24 and 48 h of ischemic
stroke diagnosis in patients who received intravenous thrombolysis
f
One patient with a stroke due to multiple etiologies was treated with combination antiplatelet (single or dual) with therapeutic anticoagulation
NIHSS Denotes National Institutes of Health Stroke Scale, IQR Interquartile range, CT Computed tomography, MRI Magnetic resonance imaging, HI-1 Denotes
hemorrhagic infarction grade 1 (petechial hemorrhage), HI-2 Hemorrhagic infarction grade 1 (confluent petechiae), PH-1 Parenchymal hematoma grade 1
(confluent hemorrhage within < 30% of infarct bed), PH-2 Parenchymal hematoma grade 2 (confluent hemorrhage within > 30% of infarct bed and having
mass effect), ICU intensive care unit and mRS modified Rankin Scale

incrementally greater probability of mortality (Fig. 1),
with the total score having a strong discriminatory
power to predict in-hospital mortality (area under the

curve 0.79, 95%CI 0.70–0.88). Three or more points indicated an 88.9% sensitivity and 53.0% specificity for the
outcome of in-hospital mortality.
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Table 3 Multivariable logistic regression model evaluating predictors for cryptogenic stroke in Covid-19 patients
Variable

Univariate analysis

Multivariable analysis

OR (95% CI)

p-value OR (95% CI)

0.98 (0.75–1.27)

0.86

Male sex

1.32 (0.64–2.73)

0.45

White race

1.06 (0.46–2.42)

> 0.9

Hispanic ethnicity

1.44 (0.99–2.10)

0.05

Hypertension

0.94 (0.43–2.06)

0.87

Diabetes mellitus

0.94 (0.46–1.93)

0.87

Dyslipidemia

0.70 (0.33–1.45)

0.34

Congestive heart failure

0.35 (0.12–1.02)

0.05

Active tobacco use

0.76 (0.21–2.75)

0.68

Prior stroke

1.86 (0.53–6.47)

0.33

Chronic renal insufficiency (stage III/IV or dialysisdependent)

0.61 (0.15–2.50)

0.50

Chronic obstructive pulmonary disease and/or asthma

0.39 (0.08–1.97)

0.26

Cancer

2.08 (0.44–9.74)

0.35

0.003 (−0.006–0.013)

0.49

Cortical infarction

0.40 (0.14–1.16)

0.09

Large vessel occlusion

0.95 (0.37–1.95)

0.70

Admission WBC (× 1000/mL)

0.02 (0.002–0.04)

0.03

Admission lymphocyte count (× 1000/mL)

0.0001 (−0.12–0.12)

> 0.9

Admission platelet count (× 1000/mL)

0.0004 (−0.0003–
0.001)

0.22

D-dimer (per mcg/mL)

0.009 (0.002–0.017)

0.02

C-reactive protein (per mg/dL)

0.001 (−0.0008–0.003)

0.23

Age, per decade

p-value

Dropped from model due to nonsignificance

Medical history

Baseline NIHSS

a

0.15 (0.05–0.44)

< 0.01

Imaging

Laboratory data

Dropped from model due to nonsignificance

a

Dropped from model due to nonsignificance

1.73 (0.98–3.04)

0.06

Variables were entered into the multivariable model if they were significant to p < 0.2 in univariate regression (Hispanic ethnicity, congestive heart failure, cortical
infarction, elevated d-dimer, elevated admission white blood cell count). Variables were retained if they remained significant to p < 0.2. Laboratory values indicate
serologic studies collected closest to the time of stroke onset, unless otherwise noted
a
Variables in which β with 95% confidence interval were used to estimate the effect on the outcome of cryptogenic stroke in univariate analysis. If included in
the multivariable model, this effect is displayed as an odds ratio with 95% confidence interval. Multivariable regression model was clustered by site

Discussion
In this observational cohort of more than 14,000
COVID-19 patients treated at 31 hospitals in 4 countries, we found a high proportion of strokes among patients with COVID-19 were attributed to a cryptogenic
mechanism (42%). This finding is concordant with the
growing literature indicating a high prevalence of cryptogenic stroke in COVID-19, [6, 13, 20, 21] with increasing
data suggesting the novel human coronavirus may be a
novel stroke mechanism. In this study, a cryptogenic
stroke diagnosis was made at the judgment of the treating vascular neurologist and was inclusive of strokes
with incomplete workup. Use of more stringent trial criteria for “cryptogenic stroke” (which requires thorough

evaluation for cardiac and vascular causes of cerebral infarction) in the present study would certainly strengthen
the observed association implicating COVID-19 as a potentially unique stroke mechanism. However, we did not
centrally adjudicate vascular, echocardiographic, or parenchymal imaging in order to confirm the diagnosis of
cryptogenic infarction. Our determination of cryptogenic
stroke is congruent with many published reports which
did not report a detailed methodology for determination
of cryptogenic mechanism, [22] did not require intracranial vascular imaging, [23] or included patients for
whom workup could not be completed [20]. Therefore,
we do not believe the clinical determination of cryptogenic stroke to be a significant limitation of this analysis.
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Table 4 Outcome measures
p-valueb p-valuec
All patients acute Cryptogenic Cardioembolic Large vessel Small vessel Other
stroke
stroke
stroke
(n = 11)
ischemic strokea stroke
(n = 156)
(n = 55)
(n = 35)
(n = 15)
(n = 4)
Hemorrhagic transformation of
infarction, no. (%)

17/98 (17.4)

6/42 (14.3)

3/26 (11.5)

0/8 (0)

0/4 (0)

4/7
(57.1)

Grade of hemorrhage

0.05
> 0.9

HI-1

7/17 (41.2)

3/6 (50.0)

1/3 (33.3)

n/a

n/a

2/4
(50.0)

HI-2

2/17 (11.8)

1/6 (16.7)

0/3 (0)

n/a

n/a

1/4
(25.0)

PH-1

4/17 (23.5)

1/6 (16.7)

1/3 (33.3)

n/a

n/a

1/4
(25.0)

0.55
0.82

PH-2

4/17 (23.5)

1/6 (16.7)

1/3 (33.3)

n/a

n/a

0/4 (0)

Symptomatic ICHd, no. (%)

1/14 (7.1)

1/4 (25.0)

0/3 (0)

n/a

n/a

0/4 (0)

> 0.9

Transfer to ICU, no. (%)

69/145 (47.6)

26/52 (50.0)

11/33 (33.3)

10/15 (66.7)

0/4 (0)

10/11
(90.9)

< 0.01

0.36

Intubation, no. (%)

51/139 (36.7)

17/47 (36.2)

7/32 (21.9)

4/15 (26.7)

0/4 (0)

7/11
(63.6)

0.08

0.56

0.57

0.55

Discharge disposition, no. (%)
Home

34/136 (25.0)

11/50 (22.0)

9/29 (31.0)

4/14 (28.6)

2/4 (50.0)

5/11
(45.5)

Acute inpatient rehabilitation

18/136 (13.2)

8/50 (16.0)

3/29 (10.3)

1/14 (7.1)

1/4 (25.0)

2/11
(18.2)

Skilled nursing facility or
subacute rehabilitation

20/136 (14.7)

5/50 (10.0)

6/29 (20.7)

4/14 (28.6)

0/4 (0)

2/11
(18.2)

Long-term acute care

5/136 (3.7)

2/50 (4.0)

1/29 (3.5)

2/14 (14.3)

0/4 (0)

0/11 (0)

> 0.9

Other acute care facility

7/136 (5.2)

3/50 (6.0)

3/29 (10.3)

0/14 (0)

0/4 (0)

0/11 (0)

Hospice

2/136 (1.5)

1/50 (2.0)

0/29 (0)

0/14 (0)

0/4 (0)

1/11
(9.1)

Expired during hospitalization

53/139 (38.1)

20/50 (40.0)

7/29 (24.1)

3/14 (21.4)

1/4 (25.0)

1/11
(9.1)

Modified Rankin Scale at
discharge, median (IQR)

4 (2–6)
(n = 139)

5 (3–6)
(n = 51)

4 (2–5)
(n = 32)

4 (2–5)
(n = 14)

1 (0–4)
(n = 4)

3 (2–4)
(n = 10)

0.20

0.07

Discharge mRS 0–2, no. (%)

35/139 (25.2)

11/51 (21.6)

11/32 (34.4)

4/14 (28.6)

3/4 (75.0)

3/10
(30.0)

0.21

0.14

53/139 (38.1)

20/50 (40.0)

7/29 (24.1)

3/14 (21.4)

1/4 (25.0)

1/11
(9.1)

0.18

0.05

In-hospital mortality, no. (%)
a

Acute ischemic stroke includes suspected or radiographically-confirmed cases, and in patients with multiple possible stroke mechanisms (n = 9). Patients with
multiple stroke mechanisms were not included in the subsequent columns in order to minimize heterogeneity
P-values indicate categorical comparisons between all stroke subtypes
c
P-values indicate comparisons between cryptogenic and non-cryptogenic stroke subtypes (including strokes due to multiple possible etiologies)
d
Symptomatic ICH defined as a PH-2 grade hematoma with worsening of the NIHSS by 4 or more points
b

Perhaps the most important observation in this cohort is the relationship between stroke mechanism
and in-hospital mortality. When compared to other
discharge dispositions, death was the most common
singular discharge disposition in this cohort of stroke
patients. When death was evaluated as a bivariate
outcome, having a cryptogenic stroke mechanism was
significantly and independently predictive of inhospital mortality. The high mortality rate is consistent with other cohorts [6, 13, 20] and adds to the results of one recent systematic review and metaanalysis demonstrating a 5-fold increase in in-hospital

mortality among COVID-19 stroke patients when
compared to their contemporary noninfected or historical controls [21]. It should be noted that patients
in the present cohort contributed to this metaanalysis by Katsanos and colleagues; however the patients in the present study did not contribute to the
comparison of in-hospital mortality rates among
COVID-19 stroke patients and COVID-19-negative
controls.
In our study, admission white blood cell count, creactive protein, and D-dimer levels were significantly
higher for patients later diagnosed with cryptogenic
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Fig. 1 Mortality rate among patients with COVID-19 and stroke according to mortality score. One point was assigned for each clinical factor up to
a total of 5 possible points: age 60 or more, male sex, NIHSS 10 or more, history of diabetes, and cryptogenic stroke

stroke. It has been described that SARS-CoV-2 infection
is linked to a prothrombotic state with elevated D-dimer
levels [24]. This finding also suggests that hypercoagulability could be one of the causes underlying this high
proportion of cryptogenic strokes [25]. The high incidence of intracranial occlusion (46%) and cortical
(74.4%) strokes also suggest a disproportionate number
of patients with embolic strokes who suffer from
COVID-19. These findings are in keeping with recently
published observations from a New York hospital system
[20]. Together, these observations validate the relationship between a significant inflammatory and/or prothrombotic state and clinically significant stroke that is
unrelated to other traditional stroke risk factors (e.g.,
cervical artery atherosclerosis or atrial fibrillation). Furthermore, the higher mortality rate observed in patients
with cryptogenic stroke speaks to the severity of
COVID-19 experienced by these patients. On the other
hand, diagnostic workup for patients in this study (and
in other studies) [20, 22, 23] may not have been completed for some patients with COVID-19 in whom care
was being withdrawn or who expired soon before
workup could have been completed. This might have
confounded our observation of a high rate of cryptogenic stroke and associated mortality, as reported in one
prior study [11].
Due to the strong relationship between cryptogenic
stroke and early mortality, we derived a simple risk score
for mortality that could serve as a useful tool in

hospitalized stroke patients with COVID-19 when making long-term plans of care. Patients in this cohort who
met each of the 5 criteria (age, male sex, diabetes, NIHS
S 10+, cryptogenic stroke) were at an 80% chance of inhospital mortality, whereas those who met at least 3 criteria were still more likely to die than to survive
hospitalization. However, this score is not without limitations, and it certainly warrants external validation.
First, the NIHSS is not a specific indicator of stroke severity in critically ill patients with COVID-19, as it can
be confounded by sedation. Second, a patient’s history of
diabetes does not reflect how well or poorly controlled
the medical condition is, and we did not evaluate the
risk of mortality based on markers of diabetic control
(e.g., hemoglobin A1c) or duration of disease. Further,
the diagnosis of a stroke as ‘cryptogenic’ may be contingent upon which testing was or was not pursued to
evaluate the proximate cause of stroke in a critically ill
patient. As in previously published reports of cryptogenic stroke in COVID-19 patients [20], patients with a
high probability of dying after a severe stroke may not
have undergone a more comprehensive workup, and
therefore could have been prematurely classified as
‘cryptogenic’. Determination of a stroke being cryptogenic on the basis of incomplete workup due to high
probability of imminent death or pursuit of comfort
measures may have falsely contributed to its association
with in-hospital mortality. That said, as we have previously reported [7], the median delay from stroke onset
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to death was 4 days in this cohort, (IQR 1–10 days)
which suggests that echocardiographic and vascular imaging could have been performed in advance of
expiration.
While this study is one of the largest observational cohorts of consecutive COVID-19 patients with cerebrovascular complications, it is limited by its retrospective
nature and the completeness of data elements that were
abstracted from the medical record. The imaging findings were not centrally adjudicated. Selection and interpretation of diagnostic tests were made at the discretion
of the treating physician, and the derivation of a simplified mortality score warrants external validation. That
said, our data reflect a large cohort of consecutive patients evaluated at many sites and reflect the diverse experiences in care of patients with stroke and COVID-19.

Conclusions
Although the overall incidence rate of acute ischemic
stroke in hospitalized patients with COVID-19 is small,
there is a higher than expected proportion of patients
with cryptogenic stroke. Furthermore, patients with
cryptogenic stroke and COVID-19 are at a significantly
greater risk of early mortality when compared to patients
with COVID-19 and known, traditional stroke mechanisms. The relationship between cryptogenic stroke in
COVID-19 and mortality may be driven by more severe
inflammatory or prothrombotic disease in COVID-19. A
simple 5-point score may be useful in clinical decision
making for patients at a low risk of short-term survival,
however this score requires external validation.
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